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Lohith et al. (Mol Autism 4:15, 2013) recently identified increased metabotropic glutamate receptor 5 (mGluR5)
expression in the frontal cortex (FC) of subjects with fragile X syndrome. These results are consistent with
postmortem findings in cerebellar vermis and FC of subjects with autism (Fatemi and Folsom, Mol Autism 2:6, 2011;
Fatemi et al. Anat Rec 294:1635–1645, 2011), suggesting that increased mGluR5 signaling is common to multiple
autism spectrum disorders. Increased mGluR5 signaling may be associated with reduced phosphorylation of fragile
X mental retardation protein (FMRP), which could result in the inactivation of this protein. In the current study, we
report on reduced expression of phosphorylated FMRP in cerebellar vermis of adults and children with autism and
in FC of adults with autism.
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We have read with great interest the recent article by
Lohith et al. [1] regarding increased expression of
metabotropic glutamate receptor 5 (mGluR5) in the
frontal cortex of individuals with fragile X syndrome
(FXS). The results are consistent with our published work
of increased expression of mGluR5 in the superior frontal
cortex of children with autism [2]. Moreover, we have
also demonstrated increased mGluR5 expression in the
cerebellar vermis of children with autism [3]. Taken
together, our data and those of Lohith et al. [1] suggest
that increased brain expression of mGluR5 may be a* Correspondence: fatem002@umn.edu
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reproduction in any medium, provided the orspecific marker of autism spectrum disorders. In contrast,
we have identified reduced expression of mGluR5 in
the brains of subjects with schizophrenia and bipolar
disorder [4].
Increased mGluR5 expression in autism and FXS is
associated with reduced or absent expression of fragile
X mental retardation protein (FMRP) [5]. We have shown
reduced FMRP expression in the cerebellar vermis and
superior frontal cortex of individuals with autism [2,3]
and from the lateral cerebellum and superior frontal
cortex of subjects with schizophrenia, bipolar disorder,
and major depression [4,6]. Additionally, levels of several
targets of FMRP including ras-related C3 botulinum
toxin substrate 1 (RAC1), homer 1, striatal-enriched protein
tyrosine phosphatase (STEP), and amyloid beta A4
precursor protein (APP) are also altered significantly
in subjects with autism [7] pointing to involvement of
mGluR5-FMRP signaling abnormalities in autism. FMRP
has been found to colocalize with stalled, translationallyLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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499, whereas dephosphorylated FMRP associates with
actively translating ribosomes [8]. Thus, phosphorylated
FMRP is seen as a translational repressor, while dephos-
phorylation of FMRP, mediated by mGluR signaling,
may lead to derepression of protein translation.
We have recently completed a preliminary study of
serine 499 phosphorylated FMRP protein levels in the
cerebellar vermis in adults (n = 5 controls and 5 adults
with autism) and children (n = 3 controls and 4 children
with autism), and in the superior frontal cortex in adults
(n = 6 controls and 10 adults with autism) and children
(n = 6 controls and 8 children with autism). All values
were normalized against neuronal specific enolase (NSE)
and data were expressed as ratios of phosphorylated
FMRP/NSE. We found significant reductions in phosphor-
ylated FMRP/NSE in the vermis of adults and children
with autism when compared with controls (Figure 1).
There was also a significant reduction in phosphorylated
FMRP in the Brodman area 9 (BA9) in adults with autism,
whereas there was no significant change in the BA9 of
children (Figure 1). Age, gender, and postmortem interval
(PMI) were examined as possible confounders. In those
cases where the relationship between confounding vari-
ables and phosphorylated FMRP showed moderate or
greater effect sizes (for example, r >0.3) we used analysis
of covariance (ANCOVA) to co-vary their effects. In
none of these cases were significant differences between
controls and subjects with autism in phosphorylated
FMRP changed by the presence of these covariates. Our
new finding of a reduction in phosphorylated FMRP in
the cerebellar vermis of children with autism may beFigure 1 Ratios of serine 499 phosphorylated Fragile X mental
retardation protein (FMRP)/neuronal specific enolase (NSE) in
the cerebellar vermis and Brodman area 9 (BA9) of subjects
with autism versus matched controls. Significant reductions were
found in subjects with autism in the vermis of adults (P <0.012) and
children ( P <0.0018), and in BA9 in adults (P <0.0001).associated with increased activity of mGluR5, which could
result in dephosphorylation of FMRP, and its subsequent
ubiquitination and degradation [9]. Current basic science
reports showing abnormalities in FMRP-mGluR5 signaling
and their targets [1-3,7] support the usefulness of new
novel treatments in autism spectrum disorders.
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